论文部分内容阅读
目的:研究氨氯地平与厄贝沙坦片联用治疗2型糖尿病患者脑出血急性期的疗效。方法:2013年3月~2014年5月,102例2型糖尿病急性脑出血患者按入院顺序分为观察组(51例)和对照组(51例)。两组均给予常规脱水、降糖治疗。在此基础上,对照组加用厄贝沙坦片治疗,观察组在对照组基础上再联合使用氨氯地平片。治疗2个月后观察两组患者治疗前后血糖水平变化和NIHSS评分,比较两组患者治疗后的不良反应状况。结果:治疗后,两组患者平均血糖波动值、血糖平均绝对差,收缩压、舒张压均较前显著降低(P<0.05),且观察组水平显著低于对照组(P<0.05)。治疗后第2周、2个月两组患者NIHSS评分均较治疗前明显下降(P<0.05),且同期观察组患者的NIHSS评分显著低于对照组(P<0.05)。两组药品不良反应差异无统计学意义(P>0.05)。结论:氨氯地平与厄贝沙坦片联用治疗2型糖尿病急性脑出血患者,能明显降低患者的血糖波动值,使患者的NIHSS评分得以明显改善,其疗效较好,值得广泛推广使用。
Objective: To study the efficacy of amlodipine combined with irbesartan in the treatment of acute cerebral hemorrhage in type 2 diabetic patients. Methods: From March 2013 to May 2014, 102 patients with type 2 diabetes mellitus with acute cerebral hemorrhage were divided into observation group (51 cases) and control group (51 cases) according to admission order. Both groups were given routine dehydration, hypoglycemic treatment. On this basis, the control group plus irbesartan tablets treatment, the observation group in the control group based on the combined use of amlodipine tablets. Two months after treatment, the changes of blood glucose level and NIHSS score were compared between the two groups before and after treatment, and the adverse reactions after treatment were compared between the two groups. Results: After treatment, mean blood glucose fluctuation, absolute mean difference of blood glucose, systolic blood pressure and diastolic blood pressure were significantly decreased in both groups (P <0.05), and the level of observation group was significantly lower than that of control group (P <0.05). The NIHSS scores of the two groups at 2 weeks and 2 months after treatment were significantly lower than those before treatment (P <0.05), and NIHSS scores in the observation group were significantly lower than those in the control group (P <0.05). Adverse reactions between the two groups showed no significant difference (P> 0.05). Conclusion: The combination of amlodipine and irbesartan in the treatment of acute cerebral hemorrhage patients with type 2 diabetes mellitus can significantly reduce the value of blood glucose in patients, which can significantly improve the NIHSS score of patients. The effect is good and should be widely used.